Skip to content
ClinCalc Pro
Menu
Topical corticosteroid (ocular anti-inflammatory)

Dexamethasone 0.1% Eye Drops (Maxidex)

Brand names: Maxidex

Dexamethasone eye drops are a potent topical corticosteroid used to treat steroid-responsive ocular inflammation, including anterior uveitis and post-operative inflammation.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

Dexamethasone binds glucocorticoid receptors to suppress the inflammatory cascade, reducing leucocyte infiltration, vascular permeability and release of inflammatory mediators.

Prescribing in practice

  • Topical ocular corticosteroids can raise intraocular pressure and promote cataract formation with prolonged use, and may worsen or mask ocular infection, so they should be used under ophthalmic supervision.
  • They are contraindicated in untreated infective conditions such as herpes simplex keratitis (dendritic ulcer) and most acute purulent eye infections.
  • Treatment should generally be tapered rather than stopped abruptly after prolonged courses to avoid rebound inflammation.

Monitoring

Monitor intraocular pressure during prolonged use and review the eye for evidence of infection or lens changes.

Counselling the patient

  • Use the drops exactly as prescribed and do not extend the course without ophthalmic review.
  • Report any eye pain, reduced vision or worsening redness promptly.
  • Attend follow-up appointments so eye pressure can be checked.

Evidence & guidelines

Topical corticosteroids are standard therapy for steroid-responsive ocular inflammation, with use guided by the SPC and ophthalmic practice.

Reference: RCOphth Uveitis Guidelines; Maxidex SPC; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.